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Abstract
Background: French general practitioners (GPs) were enrolled in a new payment system in January 2012. As part of
a national agreement with the French National Ministry of Health, GPs were asked to decrease the proportion of
patients who continued their benzodiazepine treatment 12 weeks after its initiation and to decrease the proportion
of patients older than 65 who were prescribed long half-life benzodiazepines. In return, GPs could expect an extra
payment of up to 490 euros per year. This study reports the evolution of the corresponding prescribing practices of
French GPs during that period regarding patients who were prescribed a benzodiazepine for the first time.
Methods: The national healthcare system's administrative database was used to report the longitudinal follow-up
of two historical cohorts of French patients from the Pays de la Loire area.
Study patients: The “2011” and “2012” cohorts included all patients who initiated benzodiazepine regimens from
April 1 to June 30 in 2011 and 2012, respectively.
The primary outcomes were the proportion of those study patients who continued benzodiazepine treatment after
12 weeks and the proportion of study patients >65 years who were prescribed long half-life benzodiazepines.
Analyses were performed using a multi-level regression.
Results: In total, 41,436 and 42,042 patients initiated benzodiazepine treatment in 2011 and 2012, respectively. A
total of 18.97% of patients continued treatment for more than 12 weeks in 2012, compared with 18.18% in 2011. In
all, 27.43% and 28.06% of patients >65 years continued treatment beyond 12 weeks in 2011 and 2012, respectively.
The proportion of patients >65 years who were prescribed long half-life benzodiazepines decreased from 53.5% to
48.8% (p < 0.005) due to an increase in short half-life benzodiazepine prescriptions. Patients >65 years who were
prescribed short half-life benzodiazepines were more likely to continue treatment after 12 weeks (p < 0.005).
Conclusions: Despite the pay-for-performance strategy, the number of short half-life benzodiazepine prescriptions
increased between 2011 and 2012, and the number of long half-life benzodiazepine initiations remained
unchanged. Reducing the proportion of long half-life benzodiazepine prescriptions might be counterproductive
because prescribing short half-life benzodiazepines was associated with higher rates of continuation beyond the
recommended duration.
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Background
Benzodiazepines are known to have hypnotic, anxiolytic,
anticonvulsant, myorelaxant and amnesic properties.
Many indications have been recognised due to benzodi-
azepines’ anxiolytic effects, including acute stress reac-
tions, episodic anxiety, generalised anxiety and initial
treatment for severe panic. In 2010, 15 to 20% of the
French population was prescribed a benzodiazepine, which
is twice as high as the percentage in other European
countries [1]; thus, reducing the number of benzodi-
azepine prescriptions is a priority in France [2]. The
extent of these prescriptions increases the number of
potentially adverse effects of this drug class in the gen-
eral population [3,4] and may affect mortality [5,6].
Previous research in the elderly population also dem-
onstrated an association between benzodiazepine con-
sumption and morbidity [3,4,6]. Moreover, Billioti de
Gage recently published a cohort study demonstrating
that the use of benzodiazepines in patients older than
65 was associated with an increased risk of dementia
upon a 15-year follow-up [7].
Therefore, improving prescribing practices is a priority.
Guidelines recommend a short-term prescription for ben-
zodiazepines [8]; this period is limited to 2 to 4 weeks in
most countries [9] and 12 weeks in France [10]. How-
ever, many publications have reported difficulties in
managing benzodiazepine withdrawal in patients who
became dependent because of long-term use [11-13].
Clay [1] showed that the anti-benzodiazepine campaigns
initiated in most countries from 2005-2011 were unsuc-
cessful and that the use of benzodiazepines did not de-
crease, despite national recommendations. Another way
to limit benzodiazepine side effects might be to promote
the prescription of short half-life benzodiazepines instead
of long half-life benzodiazepines in patients older than
65 years [14-17]. In sum, the modification of benzodi-
azepine consumption in patients who have used benzodi-
azepines for many years remains a challenge [18].
In 2011, French policy makers speculated that a pay-
for-performance intervention might motivate GPs to im-
prove their practices. As part of a national agreement
with the French National Ministry of Health and the fed-
erations of French GPs, four different priorities were de-
fined: medical surgery organisation, quality of chronic
disease management, prevention practices, and medico-
economic efficiency. The overall national investment
dedicated to the pay-for-performance intervention was
estimated at 282 million euros [10]. Physicians were thus
enrolled in this new reimbursement and payment system
in January 2012 [10]. For each GP, the extra-payment
package was based on a grading scale assessing 29 in-
dicators, with a maximum of 1300 points [10]. The global
extra-payment amount for each GP was estimated at 5000
euros. Benzodiazepine prescribing practices were assessed
based on two indicators with a related specific extra-
payment amount of 490 euros [10]. As part of the pay-
for-performance intervention, GPs were asked to de-
crease the proportion of patients who continued their
benzodiazepine treatment 12 weeks after its initiation to
12% and to decrease the proportion of patients older
than 65 who were prescribed long half-life benzodiaze-
pines to 5%.
This study reports the evolution of the prescribing
practices of French GPs between 2011 and 2012 regard-
ing patients who were prescribed a benzodiazepine for
the first time. Decreases in the following indicators were
expected: the proportion of patients who did not inter-
rupt their benzodiazepine treatment 12 weeks after its
initiation and the proportion of patients older than 65 years
who were prescribed a long half-life benzodiazepine.
Methods
Design, setting, and patients
This study used the national health care system's admin-
istrative database to report the longitudinal follow-up of
two historical cohorts. Access to anonymized data was
provided by the National Healthcare Insurance services
who participated to the study, after permission of the
Healthcare Insurance authorities. All eligible patients
lived on the French West Coast in the Pays de la Loire
geographic area (3,571,495 inhabitants), were older than
16 years and were affiliated with one of the 1,350 GPs
who practised in the geographic area at the beginning of
the study (April 1, 2011).
The “2011 cohort” included all patients who had been
prescribed a benzodiazepine from April 1 to June 30,
2011, and had not taken any benzodiazepines during the
preceding 4 months. The “2012 cohort” included all pa-
tients who had been prescribed a benzodiazepine from
April 1 to June 30, 2012, and had not taken any benzodi-
azepines during the preceding 4 months.
The drugs included in this study were classified as ei-
ther long half-life benzodiazepines (bromazepam, cloba-
zam, potassium clorazepate, diazepam, ethyl loflazepate,
nordazepam, prazepam, flunitrazepam and nitrazepam)
or short half-life benzodiazepines (alprazolam, clotiaze-
pam, lorazepam and oxazepam) in accordance with an
international classification selected by policy makers and
provided to the GPs [19]. Hypnotics and “Z-drug” pre-
scriptions (zopiclone, zolpidem and zaleplon) were not
included because these drugs have a 4-week prescription
limitation in France and prescribing these drugs was not
a concern in the pay-for-performance experiment.
Data collection
Benzodiazepine characteristics included the generic
name, prescription dates and delivery dates. All benzodi-
azepine deliveries (i.e., instances of dispensing medication)
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recorded in the database were extracted from April 1 to
June 30, 2011, and from April 1 to June 30, 2012, and the
corresponding patients were identified. Other benzodiazep-
ine deliveries were tracked for a longer period for each
patient, from December 1, 2010, to August 20, 2011, and
from December 1, 2011, to August 20, 2012. The propor-
tion of patients older than 65 years who received a long
half-life benzodiazepine was calculated. Only the first
benzodiazepine was considered in the analysis when
a patient had been successively prescribed two different
benzodiazepines.
The data collected included patient characteristics, such
as gender, age, socioeconomic status (characterised
by specific reimbursement facilities) and two types of
medical history information: diagnosis of a chronic dis-
ease (including patients benefiting from “disorder of long
duration” reimbursement status) and whether a GP or a
psychiatrist initiated the prescription.
Primary outcome measures
All patients who received enough tablets to consume a
benzodiazepine for a period longer than 12 weeks (based
on the standard dose) were classified as “continuing pa-
tients”. The proportion of patients who did not interrupt
their benzodiazepine treatment 12 weeks after its initi-
ation (i.e., continuing patients) was calculated using the
following ratio: number of continuing patients/number
of patients in the cohort.
The proportion of patients who were prescribed a long
half-life benzodiazepine was calculated using the follow-
ing ratio: number of patients with a long half-life benzo-
diazepine prescription/overall number of patients with a
benzodiazepine prescription.
Statistical analysis
All analyses were performed using R 2.12.0 statistical
software (R Foundation, Vienna, Austria), and Yates
correction was used when required [20]. A multi-level
regression analysis was used. GPs were considered as
random effect, whereas patient age, sex, residency loca-
tion, and socio-economic status were considered as
fixed factors. An alpha level of 0.05 was chosen to as-
sess statistical significance.
Ethics statement
Neither ethics approval nor a specific written informed
consent from participants was required in France for this
retrospective database study [21].
Results
Patient and prescriber characteristics at benzodiazepine
initiation are provided in Table 1. In total, 41,436 and
42,042 patients initiated benzodiazepine treatment from
April to June 2011 and April to June 2012, respectively.
GPs provided more than 99% of all prescriptions in 2011
and 2012. Alprazolam was the most prescribed drug
(corresponding to 41.24% of all prescribed benzodiazep-
ine in 2011 and 43.69% in 2012), followed by bromaze-
pam (33.31% in 2011 and 28.72% in 2012). Those
patients who were prescribed two benzodiazepines dur-
ing the study periods in 2011 and 2012 numbered 1,703
and 1,805, respectively.
The proportion of patients who did not interrupt their
benzodiazepine treatment 12 weeks after its initiation
(corresponding to the first indicator) is shown in Table 2.
In the overall population, 18.18% and 18.97% of patients
continued the treatment for more than 12 weeks in 2011
and in 2012, respectively (p = 0.030), whereas 27.43% and
28.66% of patients older than 65 years, respectively, contin-
ued treatment beyond the 12-week period (p = 0.30).
The distributions of short and long half-life benzodi-
azepine use in patients older than 65 years (correspond-
ing to the second indicator) are presented in Table 3.
The percentage of patients older than 65 who were pre-
scribed a long half-life benzodiazepine decreased from
53.5% to 48.8% (p < 0.005) between 2011 and 2012.
Table 4 synthesises the results of the two previous
indicators. This table shows that patients older than
65 years who were prescribed a short half-life benzodi-
azepine were more likely to continue the treatment be-
yond the 12-week limit compared with those prescribed
a long half-life benzodiazepine (p < 0.005).
Discussion
Main findings
The proportion of patients who continued their benzodi-
azepine prescriptions beyond the recommended dur-
ation did not decrease between 2011 and 2012, despite
recommendations and financial incentives. On the con-
trary, this database study shows a slight but significant
increase in the number of patients who did not interrupt
Table 1 Patient and prescriber characteristics at
benzodiazepine initiation (France, 2011-2012)
2011 2012
N = 41,393 N = 41,980
Patient characteristics n % n %
Agea 51.77; 51 (17.66) 52.66; 52 (17.84)
Male 13,696 33.09 14,016 33.39
Place of residence
Rural 14,096 34.05 14,617 34.82
Urban 25,911 62.60 26,627 63.43
Unknown 1,386 3.35 736 1.75
Prescriber characteristics
Initiation by GP 41,357 99.91 41,893 99.79
aMean; median (SD).
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benzodiazepine consumption. One in five patients who
initiated a benzodiazepine regimen continued drug in-
take beyond the recommended 12-week duration, which
increased to more than one in four patients over the age
of 65. The proportion of long half-life benzodiazepine
prescriptions decreased in the latter population, which
could be attributed to a 20% increase from 2011 to 2012
in the overall prescription of short half-life benzodiaze-
pines, compared with no change in long half-life benzodi-
azepine prescription. This study shows that substituting
long half-life benzodiazepines with short half-life benzodi-
azepines might be counterproductive because the prescrip-
tion of short half-life benzodiazepines was significantly
associated with treatment continuation beyond the recom-
mended duration.
Strengths and weaknesses
The pay-for-performance intervention that was evalu-
ated in this study was implemented as a nationwide
strategy in a country in which these drugs are exten-
sively prescribed. Policy makers and GPs organisations
selected the objectives and the related outcomes of their
own initiatives. Our study was designed to be consistent
with the objectives and evaluations put forth by policy
makers, and the research findings should be relevant to
GPs in clinical practice.
The study has several limitations because policy
makers primarily designed the implemented intervention
without researchers’ opinions. This pay-for-performance
study was an uncontrolled before-and-after study, which
did not allow the assertion of a causal link between the
intervention and the observed changes [22,23]. An op-
tional pay-for-performance system had been piloted in
France previously; consequently, the effective novelty
of the pay-for-performance scheme probably concerned
only two-thirds of the GPs who participated to the study.
Information in this study was extracted from large data-
bases derived from healthcare insurance systems, which
is similar to previous studies [24-26]. A limitation re-
ported in other studies of inappropriate prescribing was
that information about disease and indications could not
be considered. Drug intake could be assessed using only
proxy measures because data collection was based on
reimbursement.
Findings relative to other studies
The positive impact of financial incentives on benzodi-
azepine prescribing practices is difficult to assess. Our
results are consistent with previous evaluations of the ef-
fectiveness of pay-for-performance strategies. Evidence
of improvement in patient health is lacking [22,23].
Flodgren et al. reported that financial incentives for phy-
sicians were generally ineffective for improving compli-
ance with guideline outcomes [23]. In contrast, two recent
Table 2 Proportion of patients who did not interrupt their benzodiazepine treatment 12 weeks after its initiation
(France, 2011-2012)
2011 2012 p
N = 41,393 N = 41,980
Discontinuing patients Continuing patients Discontinuing patients Continuing patients
n, % n, % n, % n, %
All patients 33,869; 81.82 7,524; 18.18 34,018; 81.03 7,962; 18.97 0.030
Patients older than 65 years 7,180; 72.57 2,714; 27.43 7,798; 71.94 3,041; 28.06 0.30
Table 3 Short vs. long half-life benzodiazepines prescribed
to patients older than 65 years (France, 2011-2012)
2011 2012
N = 9,894 N = 10,839 p
n; % n; %
Short half-life BZDa 4,601; 46.50 5,550; 51.20 <0.005
Clotiazepam 118; 1.19 137; 1.26 0.69
Oxazepam 723; 7.31 997; 9.20 <0.005
Lorazepam 962; 9.72 1,043; 9.62 0.83
Alprazolam 2,798; 28.28 3,373; 31.12 <0.005
Long half-life BZDa 5,293; 53.50 5,289; 48.80 <0.005
Bromazepam 4,120; 41.64 3,907; 36.05 <0.005
Clobazam 115; 1.16 174; 1.61 0.008
Diazepam 64; 0.65 189; 1.74 <0.005
Ethyl loflazepate 112; 1.13 113; 1.04 0.58
Prazepam 624; 6.31 664; 6.13 0.61
Nordazepam 101; 1.02 98; 0.90 0.43
Potassium clorazepate 157; 1.59 144; 1.33 0.13
aBenzodiazepine.
Table 4 Association between benzodiazepine
discontinuation and drug half-life in patients






2011 N = 4,601 N = 5,293
Continuing patients (n; %) 1,425; 30.97 1,289; 24.35 <0.005
2012 N = 5,550 N = 5,289
Continuing patients (n; %) 1,755; 31.62 1,286; 24.31 <0.005
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Dutch studies demonstrated a link between payment facil-
ities and benzodiazepine use [27,28], although the inter-
ventions in these studies most likely had a greater impact
on patient behaviour than on GPs’ prescribing practices. In
particular, these studies evaluated the impact of benzodi-
azepine delisting by health insurance. The first study fo-
cused on indications for “anxiety” and “sleep disorders”
and demonstrated a moderate impact of delisting on the
number of benzodiazepine treatment initiations [27]. The
second study compared the number of days that each
patient underwent benzodiazepine treatment during the
2 years before and 2 years after delisting. The number of
days of treatment decreased, especially in patients with ini-
tial low intake [28].
Financial incentives for GPs did not favour the discon-
tinuation of benzodiazepine prescribing. Two interpre-
tations of this result must be considered. First, the
inappropriate practices of GPs are likely not due to a
lack of motivation. Previous studies have also shown that
GPs are aware of their actions [29]. Thus, further inter-
ventions should focus on other solutions. For instance,
cognitive behavioural therapies are recommended [30],
but no reimbursement is provided to the patient for
such therapies, even if he or she consults a psychologist
[31]. Second, patients with psychological disorders are
likely to face difficulties that require sustained long-term
care. Karanikolos reported that the prevalence of mental
health disorders in people undergoing primary care in-
creased significantly in European countries in association
with the current economic crisis and austerity policies
[32]. Many anxiety and depressive symptoms can be at-
tributed to either individual or family unemployment or
difficulties with payments [33]. Many recent publications
have also reported increasing suicide rates in European
countries [34-36], so the study periods were unfavour-
able for expectations of a decrease in benzodiazepine
consumption. In further studies, clinical assessment of
indications and distinctions among anxiety, sleep disor-
ders and other indications would facilitate an improved
focus on inappropriate long-term use of benzodiaze-
pines. GPs should reconsider treatment indications to
shift towards non-pharmacological treatments or other
drugs, such as serotonin reuptake inhibitors, to resolve
this issue regarding benzodiazepine prescriptions. These
alternative treatments could help to avoid the side ef-
fects of benzodiazepines.
The reduced proportion of long half-life benzodiazep-
ine prescriptions was consistent with the key message of
policy makers to GPs. Previous authors suggested that
reducing the use of long half-life benzodiazepines in in-
dividuals older than 65 years could reduce the risk of
sedation, falls, hip fractures, memory disorders and acci-
dents [37,38]. However, other publications did not find
the same associations [39,40]. The use of short-acting
benzodiazepines has also been associated with fall-related
injuries [41]. Therefore, the changes in physician practice
that were observed in this study might not be relevant.
Prescribers should evaluate the indication, dose and duration
of benzodiazepine treatment according to the clinical
characteristics of patients. Half-life duration is an import-
ant consideration but should not be the main reason for
choosing a benzodiazepine. Indeed, half-life benzodiazepine
classifications differ between different authors. The French
pay-for-performance intervention refers to an international
classification published by Laroche in 2007 [42], but other
studies distinguish three types of benzodiazepines: short,
intermediate and long half-life benzodiazepines [43]. Last
but not least, this study suggests that the use of short
half-life drugs might increase the risk of addiction, which
is consistent with their pharmacology [44].
Implications for clinicians and policy makers
This study emphasises the difficulties that clinicians face
in anxiety management. A key message is that substitution
of a long half-life benzodiazepine with a short half-life one
is likely suboptimal. A better substitution might be the use
of antidepressants rather than benzodiazepines for long-
term treatment [45]. Our study also demonstrated the lim-
ited impact of the pay-for-performance system on anxiety
management practices in primary care. A new approach
might be the transfer of part of the amount reserved for
the pay-for-performance system to reimbursement for
psychologist consultations in France [45].
Conclusions
The implementation of the pay-for-performance strategy
did not affect the prescription of long half-life benzodi-
azepines, while the number of prescriptions of short
half-life drugs increased between 2011 and 2012. An ad-
verse effect of this evolution was the continuation of
benzodiazepine treatments for more than 12 weeks, in-
sofar as short half-life drugs have been associated with a
higher rate of withdrawal than long half-life drugs.
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